iFyber attending Innovations in Wound Healing

The Role of Tissue Models and LC-MS in Wound Healing Research

Wound healing research increasingly depends on models that can capture more than a single functional endpoint. Measurements such as wound closure, cell migration, viability, inflammation, antimicrobial activity, reepithelialization, and extracellular matrix remodeling can establish whether a treatment produces a biological response. The next research question may be what molecular changes accompanied that response.  Human-relevant cell and tissue models provide the biological context for…
Read More →

Biomarker Analysis in Beauty R&D: How Human-Relevant Assays Reveal Product Mechanisms

Beauty and skincare R&D is increasingly focused on demonstrating not only whether a product produces a measurable effect, but also the biological mechanisms driving that response. Barrier function, inflammation, extracellular matrix remodeling, wound healing, and microbiome interactions can all provide meaningful endpoints for evaluating product performance.  Biomarker analysis adds mechanistic resolution by connecting functional outcomes with changes in specific cellular, molecular, or…
Read More →

Selecting the Right Antimicrobial Endpoints for Medical Device Product Testing

Medical device developers have more antimicrobial testing options than ever before, but selecting the right study remains a challenge. Throughout product development, teams must answer different questions about antimicrobial performance. One study may evaluate growth inhibition, while another assesses microbial killing or how an antimicrobial material performs on a device surface. The challenge is that no single…
Read More →

Building a Defensible Antimicrobial Claims Strategy for 510(k) Clearance

Medical device manufacturers developing antimicrobial technologies often prioritize early efficacy data as a primary development milestone. While antimicrobial performance is essential for 510(k) clearance, strong results alone do not automatically translate into a claim that will withstand regulatory scrutiny. As Aaron Strickland, Vice President of Research and Development at iFyber, emphasizes, the critical distinction is not…
Read More →